Andrew D. Dickinson
Net Worth

Last updated:

What is Andrew D. Dickinson net worth?

The estimated net worth of Mr. Andrew D. Dickinson is at least $56,462,187 as of 10 Dec 2024. He owns shares worth $16,336,874 as insider, has earned $23,865,313 from insider trading and has received compensation worth at least $16,260,000 in Gilead Sciences, Inc..

What is the salary of Andrew D. Dickinson?

Mr. Andrew D. Dickinson salary is $2,710,000 per year as Executive Vice President & Chief Financial Officer in Gilead Sciences, Inc..

How old is Andrew D. Dickinson?

Mr. Andrew D. Dickinson is 55 years old, born in 1970.

What stocks does Andrew D. Dickinson currently own?

As insider, Mr. Andrew D. Dickinson owns shares in one company:

Company Title Shares Price per share Total value
Gilead Sciences, Inc. (GILD) Executive Vice President & Chief Financial Officer 138,919 $117.6 $16,336,874

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD logo
GILD
Gilead Sciences, Inc.
$117.6

Andrew D. Dickinson insider trading

Gilead Sciences, Inc.

Mr. Andrew D. Dickinson has made 4 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 179,135 units of GILD stock on 29 Nov 2024. As of 10 Dec 2024 he still owns at least 138,919 units of GILD stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit 3,640 N/A N/A
Option
Common Stock 3,640 N/A N/A
Sale
Common Stock 127,930 $92.76 $11,867,171
Option
Common Stock 65,960 $72.7 $4,795,292
Option
Common Stock 43,340 $72.7 $3,150,818
Option
Common Stock 60,885 $71.91 $4,378,240
Option
Common Stock 33,660 $68.75 $2,314,125
Option
Common Stock 26,170 $57.92 $1,515,766
Sale
Common Stock 120,715 $92.77 $11,198,127
Option
Common Stock 18,630 $73.77 $1,374,335
Option
Non-qualified Stock Option (Right to Buy) 179,135 $71.78 $12,858,848
Option
Non-qualified Stock Option (Right to Buy) 26,170 $57.92 $1,515,766
Option
Restricted Stock Unit 3,641 N/A N/A
Option
Common Stock 3,641 N/A N/A
Option
Common Stock 3,639 N/A N/A
Option
Restricted Stock Unit 3,639 N/A N/A
Option
Restricted Stock Unit 3,025 N/A N/A
Option
Restricted Stock Unit 6,707 N/A N/A
Option
Common Stock 3,025 N/A N/A
Option
Common Stock 6,707 N/A N/A
Option
Restricted Stock Unit 2,617 N/A N/A
Option
Common Stock 2,617 N/A N/A
Option
Common Stock 1,912 N/A N/A
Option
Restricted Stock Unit 1,912 N/A N/A
Sale
Common Stock 5,000 $80 $400,015
Option
Restricted Stock Unit 2,619 N/A N/A
Option
Common Stock 2,619 N/A N/A
Sale
Common Stock 5,000 $80 $400,000
Option
Common Stock 2,618 N/A N/A
Option
Restricted Stock Unit 2,618 N/A N/A
Option
Restricted Stock Unit 3,025 N/A N/A
Option
Common Stock 7,394 N/A N/A
Option
Common Stock 3,025 N/A N/A
Option
Restricted Stock Unit 7,394 N/A N/A
Option
Restricted Stock Unit 1,817 N/A N/A
Option
Common Stock 1,817 N/A N/A
Option
Common Stock 1,027 N/A N/A
Option
Restricted Stock Unit 1,027 N/A N/A
Option
Restricted Stock Unit 1,912 N/A N/A
Option
Common Stock 1,912 N/A N/A
Option
Common Stock 1,027 N/A N/A
Option
Restricted Stock Unit 1,027 N/A N/A
Option
Common Stock 1,026 N/A N/A
Option
Restricted Stock Unit 3,646 N/A N/A
Option
Restricted Stock Unit 1,026 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Unit 768 N/A N/A
Option
Restricted Stock Unit 3,025 N/A N/A
Option
Restricted Stock Unit 4,108 N/A N/A
Option
Common Stock 768 N/A N/A
Option
Common Stock 3,025 N/A N/A
Option
Common Stock 4,108 N/A N/A
Option
Common Stock 1,817 N/A N/A
Option
Restricted Stock Unit 1,817 N/A N/A
Option
Common Stock 1,913 N/A N/A
Option
Restricted Stock Unit 1,913 N/A N/A
Option
Restricted Stock Unit 3,646 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Unit 3,794 N/A N/A
Option
Common Stock 3,794 N/A N/A
Option
Restricted Stock Unit 1,818 N/A N/A
Option
Common Stock 1,818 N/A N/A
Option
Restricted Stock Unit 3,046 N/A N/A
Option
Common Stock 3,046 N/A N/A
Option
Common Stock 2,306 N/A N/A
Option
Restricted Stock Unit 2,306 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Unit 3,646 N/A N/A
Option
Common Stock 769 $72.34 $55,629
Option
Restricted Stock Unit 769 $72.34 $55,629
Option
Common Stock 1,818 N/A N/A
Option
Restricted Stock Unit 1,818 N/A N/A
Option
Restricted Stock Unit 1,133 N/A N/A
Option
Common Stock 1,133 N/A N/A

Gilead Sciences key executives

Gilead Sciences, Inc. executives and other stock owners filed with the SEC: